Isocitrate dehydrogenases (IDH1/2) are key metabolic enzymes, mutated in more than 15% of AML patients, with IDH1-mutant AML cells displaying a strongly reprogrammed lipid anabolism with dysregulation of fatty acid metabolism and fluxes [145]. Here, IDH3A is linked to acute myeloid leukemia.